WINT_OUT_1 [2025-04-04 12:46:07 -0400] 3649 Bytes | 977 tokens | Cum: 977 tkns (12.21% of 8k)
==========================================================================

Booyah, my friends! It's already 12:46:06 PM on Fri Apr 04, 2025 -0400, and I've got my eyes locked on Windtree Therapeutics (WINT), pushing up to 1.565 from 1.23. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: Windtree Therapeutics (WINT)
IPO: 1984-01-25 (41 Years Ago)
Market Cap: $899,209
Shares Outstanding: 750,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

Here’s the first list of news for Windtree Therapeutics:

C1 - Mar-26-25 08:47AM - Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
C2 - Mar-24-25 08:30AM - Evofem Reports Fourth Consecutive Year of Net Sales Growth
C3 - Mar-24-25 08:30AM 08:00AM - Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules
C4 - Mar-20-25 08:27AM - Windtree shares rise as it announces agreement to become sourcing partner for Evofem
C5 - Mar-20-25 08:27AM 08:00AM - Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
C6 - Mar-04-25 08:00AM - Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart Failure
C7 - Feb-27-25 08:00AM - Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India
C8 - Feb-18-25 08:00AM - Windtree Therapeutics, Inc. Announces Reverse Stock Split

Prior AI Reports for WINT:
1. 2025-03-24 – Score: 15 – Target: 1.9900 – Highs: 2.1700 / 1.8700 / 1.74
windtree-therapeutics-struggling-with-poor-performance-and-no-revenue
2. 2025-03-20 – Score: 20 – Target: 2.6400 – Highs: 3.4800 / 2.0000 / 2.17
windtree-therapeutics-a-deteriorating-financial-picture

(Note: Highs = Same day / 2nd day / 3rd day)

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: Windtree Therapeutics (WINT).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

WINT_OUT_3 [2025-04-04 12:46:09 -0400] 1100 Bytes | 321 tokens | Cum: 1301 tkns (16.26% of 8k)
==========================================================================

Showing C1 (chunk 1 of 6): C1:
**Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics**
Date: Mar-26-25 08:47AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/evofem-expects-significant-reduction-in-phexxi-manufacturing-cost-through-agreement-with-windtree-therapeutics-302411692.html

-- Evofem's Cost to Manufacture PHEXXI will Decrease by 55% - 60% --

SAN DIEGO,March 26, 2025/PRNewswire/ --Evofem Biosciences, Inc.(OTCQB:EVFM) (Evofem or the Company) today announced that it has entered into a License and Supply Agreement (L&S Agreement) withWindtree Therapeutics, Inc.(NasdaqCM: WINT), under which Windtree will be Evofem's sourcing partner forPHEXXI® (lactic acid, citric acid and potassium bitartrate). This FDA-approved hormone-free contraceptive vaginal gel is applied 0 to 60 minutes before each act of intercourse. It prevents pregnanc

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

WINT_OUT_5 [2025-04-04 12:46:10 -0400] 1033 Bytes | 298 tokens | Cum: 1666 tkns (20.82% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-26T13:00:04Z - Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Th...
A2 - 2025-03-26T10:18:34Z - US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From ...
A3 - 2025-03-26T09:00:09Z - Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - AquaBoun...
A4 - 2025-03-24T13:13:08Z - What's Going On With Windtree Therapeutics (WINT) Stock? - Windtree Therapeutics (NASDAQ:WINT)...
A5 - 2025-03-24T12:10:50Z - 12 Health Care Stocks Moving In Monday's Pre-Market Session - Capstone Holding (NASDAQ:CAPS), Allari...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

WINT_OUT_7 [2025-04-04 12:46:13 -0400] 1099 Bytes | 326 tokens | Cum: 1994 tkns (24.93% of 8k)
==========================================================================

Showing A1 (chunk 1 of 6): A1:
**Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics By Investing.com**Date: 2025-03-26Source: {'uri': 'investing.com', 'dataType': 'news', 'title': 'Investing.com'}URL: https://www.investing.com/news/press-releases/evofem-expects-significant-reduction-in-phexxi-manufacturing-cost-through-agreement-with-windtree-therapeutics-93CH-3949443-- Evofem's Cost to Manufacture PHEXXI will Decrease by 55% - 60% --

SAN DIEGO, March 26, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced that it has entered into a License and Supply Agreement (L&S Agreement) with Windtree Therapeutics, Inc. (NasdaqCM: WINT), under which Windtree will be Evofem's sourcing partner for PHEXXI ® (lactic acid, citric acid and potassium bitartrate). This FDA-approved hormone-free contraceptive vaginal gel is ap

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

WINT_OUT_9 [2025-04-04 12:46:14 -0400] 1022 Bytes | 303 tokens | Cum: 2369 tkns (29.61% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-26T12:47:00Z - Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
B2 - 2025-03-26T10:18:34Z - US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert
B3 - 2025-01-13T13:00:00Z - Windtree Announces the Addition of Leanne Kelly to Its Board of Directors
B4 - 2024-12-09T13:00:00Z - Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia
B5 - 2024-07-10T22:16:16Z - Eagle Point Income reports NAV per share and quarterly earnings By Investing.com - Investing.com
B6 - 2024-04-18T12:00:00Z - Windtree Therapeutics Announces Reverse Stock Split

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

WINT_OUT_11 [2025-04-04 12:46:17 -0400] 775 Bytes | 209 tokens | Cum: 2580 tkns (32.25% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/25/03/n44492741/evofem-expects-significant-reduction-in-phexxi-manufacturing-cost-through-agreement-with-windtree-Evofem Biosciences has entered into an agreement with Windtree Therapeutics to reduce the manufacturing cost of its contraceptive product PHEXXI by 55-60%. This will allow Evofem to expand PHEXXI's global availability, particularly in price-sensitive markets.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

WINT_OUT_13 [2025-04-04 12:46:18 -0400] 1135 Bytes | 314 tokens | Cum: 2960 tkns (37.00% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-24 8-K Item 1.01 Entry into a Material Definitive Agrmt.

License and Supply Agrmt with Evofem Biosciences, Inc.

On March 20, 2025, Windtree Therapeutics, Inc. (the Company) entered into a License and Supply Agrmt (the LS Agrmt) with Evofem Biosciences, Inc., a Delawa...

S2 - 2025-02-18 8-K Item 7.01. Regulation FD Disclosure.

On February 18, 2025, the Company issued a press release announcing the Reverse Stock Split. The press release is furnished as Exhibit 99.1 and incorporated by reference herein.

The information in this Item 7.01, including Exhibit 99.1 atta...

S3 - 2025-02-18 8-K Item 7.01. Regulation FD Disclosure.

On February 18, 2025, the Company issued a press release announcing the Reverse Stock Split. The press release is furnished as Exhibit 99.1 and incorporated by reference herein.

The information in this Item 7.01, including Exhibit 99.1 atta...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

WINT_OUT_15 [2025-04-04 12:46:24 -0400] 1098 Bytes | 264 tokens | Cum: 3226 tkns (40.33% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 1.01 Entry into a Material Definitive Agreement.

License and Supply Agreement with Evofem Biosciences, Inc.

On March 20, 2025, Windtree Therapeutics, Inc. (the Company) entered into a License and Supply Agreement (the LS Agreement) with Evofem Biosciences, Inc., a Delaware corporation (Evofem). Pursuant to the LS Agreement, the Company will act as the supplier to Evofem of its Phexxi product outside of the United States. The term of the LS Agreement is for an initial three-year period and is automatically renewed thereafter for successive two-year periods unless either party provides 180 days notice of non-renewal or the LS Agreement is otherwise terminated in accordance with the termination provisions provided therein. The Companys manufacturing and supply obligations under the LS Agreement will commence the later of the termination of Evofems exclusivity obligations with i

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

WINT_OUT_17 [2025-04-04 12:46:35 -0400] 4763 Bytes | 1283 tokens | Cum: 4627 tkns (57.84% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+----------------------+
| Volume: 102,527 | Perf Month: -42.36% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 2.85M | Perf Quarter: -93.06% | Short Float: 6.57% | ROE: -138.34% |
+--------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 0.07 | Index: - | Short Ratio: 0.02 | ROI: -146.00% |
+--------------------+-----------------------+------------------------+----------------------+
| RSI (14): 28.43 | Market Cap: 0.82M | Short Interest: 0.05M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.46 | Shs Outstand: 0.75M | Beta: 0.78 | EPS Surprise: - |
+--------------------+-----------------------+------------------------+----------------------+
| SMA20: -29.98% | Shs Float: 0.75M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+----------------------+
| SMA50: -69.81% | Inst Own: 0.84% | Sales past 5Y: - | Earnings: Nov 27 AMC |
+--------------------+-----------------------+------------------------+----------------------+
| SMA200: -98.98% | Insider Own: 0.13% | Employees: - | |
+--------------------+-----------------------+------------------------+----------------------+
| Perf Week: -24.62% | Insider Trans: - | Debt/Eq: 1.68 | |
+--------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading if any are accessible.

No transactions recorded.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -9708000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.55
Average Volume: 6782909.39
30-Day High: 2.18
30-Day Low: 1.2

[Detailed Financials: Q3 2024]
- Total Assets: $30,448,000.0
- Total Liabilities: $23,897,000.0
- Total Equity: $4,409,000.0
- Current Assets: $3,928,000.0
- Current Liabilities: $14,426,000.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -4.23

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: N/A

[Detailed Financials: Q1 2024]
- Total Assets: $30,103,000.0
- Total Liabilities: $14,682,000.0
- Total Equity: $15,421,000.0
- Current Assets: $3,339,000.0
- Current Liabilities: $4,985,000.0

[Income Statement: Q1 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 21.98

[Cash Flow Statement: Q1 2024]
- Net Cash Flow: $0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

WINT_OUT_19 [2025-04-04 12:46:37 -0400] 687 Bytes | 169 tokens | Cum: 5065 tkns (63.31% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

WINT_IN_21 [2025-04-04 12:46:37 -0400] 126 Bytes | 29 tokens | Cum: 5124 tkns (64.05% of 8k)
==========================================================================

====================================
[2025-04-04 12:46:37] # Analysis Completed
Elapsed Time: 31.35 seconds